Sinochem DSM Responds to Prosecution of National Medicine Case for the First Time: Global Rights Protection Without Borders

On March 15, Sinochem DSM announced that its subsidiaries had filed patent lawsuits in the Netherlands and India at the same time, targeting Wichita Pharmaceuticals, the antibiotic production base of Sinopharm. Sinochem DSM accused Wichita of infringement of its enzymatic amoxicillin and demanded that the Netherlands and India prohibit the manufacture, use, import and sale of Wichita amoxicillin API and products containing it.

This is the first case of patent rights protection initiated by Sinochem DSM since its establishment in 2011. The target is the only domestic pharmaceutical enterprise Sinopharm Group that has entered the world's top 500.

How to determine Sinopharm patent infringement? Lu Fangbin said that Sinochem DSM Pharmaceuticals handed over samples of Wichita's products to an authoritative third-party laboratory for infringement testing, and ultimately concluded that Wichita's products infringed Sinochem's DSM patents, and the other party had not been authorized. After collecting sufficient evidence, the company decided to initiate a patent infringement lawsuit against Sinopharm Wichita.

According to Lu, Sinochem DSM further strengthened its global intellectual property protection last year, followed by more market information, especially for Sinochem DSM enzymatic technology. Usage. This allowed his activist team to gather more evidence.

As an important market for Sinochem DSM and the home base of Sinochem Wichita, will Sinochem DSM also launch a rights campaign? In response, Lu Fangbin said that the Netherlands and India have accepted the company's claims, but it is not convenient to disclose further arrangements in other markets, but "we will not only defend our rights in the Netherlands and India."

Talking about the understanding of China's API industry, Lu Fangbin has three impressions: production capacity is obviously oversupply; low-price competition is fierce; related companies have a big gap in environmental protection and technology. "At present, the requirements for environmental protection in China are becoming more and more stringent, and enzymatic processes and products have significant advantages over chemical methods in environmental protection, but the threshold for enzymatic technology research and development is very high, requiring enterprises to invest a lot of technology and capital."

In conjunction with the publication of the patent infringement lawsuit, Sinochem DSM also issued a press release authorizing Novartis to use two API patented technologies. A patent obtained by Sandoz is the patent that Sinochem DSM sued Sinochem for infringement. In this regard, Lu Fangbin explained that in his view, one is patent litigation and the other is patent authorization, which actually represents the two ways for API companies to maintain patent technology. Enzymatic technology, the company's core competency, is clearly the only form in which Sinochem DSM can accept its use through licensing. The company also hopes to convey this message to the industry.

Another important factor for Sinochem DSM to defend its rights is that Sinochem DSM will continue to invest in research and development of enzymatic products and sustainable production of antibiotics and statins, and the protection of intellectual property rights is particularly important, otherwise it will be at a disadvantage in the competition in the same industry.

News source:http://www.y-lp.com/pages/Article.aspx?id=5096364514279462765

This news was re-edited and reorganized by the Huaxun team and added analytical comments.